U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021

Publisher Name :
Date: 19-Jul-2016
No. of pages: 91
Inquire Before Buying

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 million by 2021, growing at a CAGR of 11% to 12% during the forecast period (2016 to 2021). The rising incidences of blood disorders and chronic diseases; rapid increase in the aging population; and increasing adoption of therapeutic plasma exchange in rare neurological, hematology, and autoimmune disorders are key factors driving the therapeutic plasma exchange market in the U.S. In this report, the market is segmented by indication, number of patients, and total number of TPE procedures performed by indication.

Therapeutic plasma exchange removes plasma components from blood. A blood cell separator extracts the patient’s plasma and returns red blood cells (RBCs) and platelets in plasma or a plasma-replacing fluid; for this purpose, 5% albumin is preferred to fresh frozen plasma (except for patients with thrombotic thrombocytopenic purpura) because it causes fewer reactions and transmits no infections. Therapeutic plasma exchange resembles dialysis but, in addition, can remove protein-bound toxic substances. A one-volume exchange removes about 66% of such components. Due to this factor, the awareness among physicians is growing, hence therapeutic plasma exchange is increasingly being adopted in the treatment of rare diseases such as Guillain-Barré syndrome, thrombotic thrombocytopenic purpura (TTP), Goodpasture syndrome, and Wegener’s Granulomatosis. This trend is expected to continue in the coming years as well.

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders. In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

The major players in the U.S. TPE market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned four strategies (market penetration, product development/innovation, market diversification, and competitive assessment) for reaping greater market shares.

This report provides insights on the following pointers:


  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the therapeutic plasma exchange market. The report analyzes the therapeutic plasma exchange market by indication, total number of TPE procedures performed, and number of patients treated with TPE in the U.S.

  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and new product launches in the therapeutic plasma exchange market

  • Market Diversification: Exhaustive information about new products, major product segments and indications, recent developments, and investments in the therapeutic plasma exchange market

  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution networks, manufacturing capabilities, and product portfolio and pricing analyses of the leading players in the therapeutic plasma exchange market

U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021

Table of Contents

1 Introduction
1.1 Objectives and Scope
1.2 Research Methodology
1.3 Market Estimation Methodology
1.4 Primary Research Methodology
1.5 Primary Respondent Profile

2 Key Insights

3 Therapeutic Plasma Exchnage Market, By Indication
3.1 Guillain-Barré Syndrome (GBS)
3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3.3 Myasthenia Gravis (MG)
3.4 Multiple Sclerosis (MS)
3.5 Neuromyelitis Optica (NMO)
3.6 Thrombotic Thrombocytopenic Purpura (TTP)
3.7 Cryoglobulinemia
3.8 Multiple Myeloma (MM)
3.9 Waldenstrom Macroglobulinemia (WM)
3.10 Hemolytic Uremic Syndrome (HUS)
3.11 Anti-GBM Disease (Goodpasture’s Syndrome)
3.12 Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis)
3.13 Post-Renal Transplant Rejection
3.14 Familial Hypercholesterolemia (Homozygous)
3.15 Anca-Associated Vasculitis

4 Appendix
4.1 Epidemiology Data
4.2 Industry Speaks
4.3 Details of Primary Respondents
4.4 Available Customizations
4.4.1 Company Profiles
4.4.1.1 Fresenius Se & Co. KGAA
4.4.1.2 B. Braun Melsungen AG
4.4.1.3 Baxter International Inc
4.4.1.4 Asahi Kasei Medical Co., Ltd.
4.4.1.5 Terumo BCT, Inc.
4.4.1.6 Haemonetics Corporation
4.4.1.7 Kawasumi Laboratories, Inc.
4.4.1.8 Hemacare Corporation
4.5 Knowledge Store: Marketsandmarkets’ Subscription Portal

List of Tables

Table 1 Data Model
Table 2 U.S.: Therapeutic Plasma Exchange Market Size, By Indication, 2014–2021 (USD Million)
Table 3 U.S.: Therapeutic Plasma Exchange Market– Patient Population and Number of Procedures
Table 4 U.S. Disease Statistics: Acute Inflammatory Demyelinating Polyneuropathy
Table 5 Treatment Guidelines & Protocols : Guillain-Barré Syndrome (GBS)
Table 6 Epidemiology : Guillain-Barré Syndrome (GBS)
Table 7 U.S. Disease Statistics: Chronic Inflammatory Demyelinating Polyneuropathy
Table 8 Treatment Guidelines & Protocols : Chronic Inflammatory Demyelinating Polyneuropathy
Table 9 Epidemiology : Chronic Inflammatory Demyelinating Polyneuropathy
Table 10 U.S. Disease Statistics: Myasthenia Gravis (MG)
Table 11 Treatment Guidelines & Protocols : Myasthenia Gravis (MG)
Table 12 Epidemiology : Myasthenia Gravis (MG)
Table 13 U.S. Disease Statistics: Multiple Sclerosis (MS)
Table 14 Treatment Guidelines & Protocols : Multiple Sclerosis (MS)
Table 15 Epidemiology : Multiple Sclerosis (MS)
Table 16 U.S. Disease Statistics: Neuromyelitis Optica (NMO)
Table 17 Treatment Guidelines & Protocols : Neuromyelitis Optica (NMO)
Table 18 Epidemiology : Neuromyelitis Optica (NMO)
Table 19 U.S. Disease Statistics: Thrombotic Thrombocytopenic Purpura (TTP)
Table 20 Treatment Guidelines & Protocols : Thrombotic Thrombocytopenic Purpura (TTP)
Table 21 Epidemiology : Thrombotic Thrombocytopenic Purpura (TTP)
Table 22 U.S. Disease Statistics: Cryoglobulinemia
Table 23 Treatment Guidelines & Protocols : Cryoglobulinemia
Table 24 Epidemiology : Cryoglobulinemia
Table 25 U.S. Disease Statistics: Multiple Myeloma (MM)
Table 26 Treatment Guidelines & Protocols : Multiple Myeloma (MM)
Table 27 Epidemiology : Multiple Myeloma (MM)
Table 28 U.S. Disease Statistics: Waldenstrom Macroglobulinemia (WM)
Table 29 Treatment Guidelines & Protocols : Waldenstrom Macroglobulinemia (WM)
Table 30 Epidemiology : Waldenstrom Macroglobulinemia (WM)
Table 31 U.S. Disease Statistics: Hemolytic Uremic Syndrome (HUS)
Table 32 Treatment Guidelines & Protocols : Hemolytic Uremic Syndrome (HUS)
Table 33 Epidemiology : Hemolytic Uremic Syndrome (HUS)
Table 34 U.S. Disease Statistics: Anti-GBM Disease (Goodpasture’s Syndrome)
Table 35 Treatment Guidelines & Protocols : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 36 Epidemiology : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 37 U.S. Disease Statistics: Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis
Table 38 Treatment Guidelines & Protocols : Wegener’s Granulomatosis
Table 39 Epidemiology : Wegener’s Granulomatosis
Table 40 U.S. Disease Statistics: Post-Renal Transplant Rejection
Table 41 Treatment Guidelines & Protocols : Post-Renal Transplant Rejection
Table 42 Epidemiology : Post-Renal Transplant Rejection
Table 43 U.S. Disease Statistics: Familial Hypercholesterolemia (Homozygous)
Table 44 Treatment Guidelines & Protocols : Familial Hypercholesterolemia (Homozygous)
Table 45 Epidemiology : Familial Hypercholesterolemia (Homozygous)
Table 46 U.S. Disease Statistics: Anca-Associated Vasculitis
Table 47 Epidemiology Data
Table 48 Details of Primary Respondents (1/8)
Table 49 Details of Primary Respondents (2/8)
Table 50 Details of Primary Respondents (3/8)
Table 51 Details of Primary Respondents (4/8)
Table 52 Details of Primary Respondents (5/8)
Table 53 Details of Primary Respondents (6/8)
Table 54 Details of Primary Respondents (7/8)
Table 55 Details of Primary Respondents (8/8)

List of Figures

Figure 1 Research Methodology
Figure 2 Market Estimation Methodology
Figure 3 Primary Research Methodology
Figure 4 Respondent Profile, By Organization
Figure 5 Respondent Profile, By Designation
Figure 6 Industry Speaks (1/3)
Figure 7 Industry Speaks (2/3)
Figure 8 Industry Speaks (3/3)
Figure 9 Marketsandmarkets Knowledge Store Snapshot
Figure 10 Marketsandmarkets Knowledge Store: Healthcare Industry Snapsho

  • Global and United States Clostridium Difficile Treatment Market Research by Company, Type & Application 2013-2025
    Published: 20-Oct-2018        Price: US 2000 Onwards        Pages: 111
    Summary Market Segment as follows: By Type - Narrow Spectrum Antibiotics - Broad Spectrum Antibiotics By Application - Hospitals - Clinics - Others By Company - Actelion Pharmaceuticals - Merck - Pfizer - Summit Therapeutics - Astellas Pharma - CRESTOVO - Da Volterra - Immuron - MGB Biopharma - Novartis - Otsuka Pharmaceutical ......
  • Global Biologic Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 136
    Biologic therapeutics drugs are genetically engineered proteins derived from human genetic material. They contain sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues. In addition, biologics drugs are derived from natural sources such as animals, humans, and microorganisms that are further utilized to make therapeutic products such as vaccines, blood components, and recombinant therapeutic proteins. Scope......
  • Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 56
    Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape. Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as th......
  • Kidney Transplant Rejection - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 175
    Kidney Transplant Rejection - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2018, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape. Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation ......
  • Peanut Allergy - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 117
    Peanut Allergy - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2018, provides an overview of the Peanut Allergy (Immunology) pipeline landscape. Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms ......
  • Global and United States Virus Like Particles Market Research by Company, Type & Application 2013-2025
    Published: 14-Oct-2018        Price: US 2000 Onwards        Pages: 117
    Summary Market Segment as follows: By Type - Adeno-Associated Virus - HIV - Hepatitis B Virus - Hepatitis C Virus - Others By Application - Vaccines - Mycoviruses - Virus Research - Therapeutic and Imaging Agents - Others By Company - GlaxoSmithKline - Merck - Novavax - Takeda - Medicago - MedImmune - TechnoVax ......
  • Global Enzyme Replacement Therapy Market Size, Status and Forecast 2018-2025
    Published: 09-Oct-2018        Price: US 3900 Onwards        Pages: 91
    This report focuses on the global Enzyme Replacement Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Enzyme Replacement Therapy development in United States, Europe and China. Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.......
  • Global Infantile Spasms Therapeutics Market Insights, Forecast to 2025
    Published: 09-Oct-2018        Price: US 3900 Onwards        Pages: 119
    This report studies the global market size of Infantile Spasms Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Infantile Spasms Therapeutics in these regions. This research report categorizes the global Infantile Spasms Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, f......
  • Global Gout Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 09-Oct-2018        Price: US 3480 Onwards        Pages: 135
    Gout is a physical conditions that affects the patient's ability to move, often also termed as unwalkable disease, and it has been around for centuries. Scope of the Report: This report studies the Gout Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gout Therapeutics market by product type and applications/en......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs